Payment overview · 2025
General Payments
$1,433.69
80 reported records · 19 companies
Healthcare provider profile · identity verified
Stephen Kyle Rogers, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · INDIANAPOLIS, IN · NPI 1609879675
Verified facts
What the public records show
CMS Open Payments records show Stephen Kyle Rogers, M.D. received $1,433.69 in general payments during 2025 across 80 reported records.
ABBVIE INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brixadi, Kerendia, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
Braeburn Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRIXADI as an associated drug or biological on 15883 records involving 5757 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Brixadi by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $337.93 | 23.6% | 20 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $211.87 | 14.8% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.26 | 11.7% | 6 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $163.97 | 11.4% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.19 | 5.7% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.91 | 5.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.30 | 4.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.33 | 3.6% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $41.91 | 2.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.25 | 2.5% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $30.92 | 2.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.68 | 1.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.19 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.79 | 1.5% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $20.76 | 1.4% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $19.60 | 1.4% | 1 | 2025 |
| Braintree Laboratories, Inc. | Unresolved — no canonical attribution shown | $14.87 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.83 | 1.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.13 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,433.69 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $211.87 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $201.68 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $167.26 | 6 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $163.97 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $82.82 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.19 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $79.91 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $76.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $70.30 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.49 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $53.43 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.95 | 3 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $20.76 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| SUFLAVE Normalized: suflave |
Drug | Braintree Laboratories, Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| SUTAB Normalized: sutab |
Drug | Braintree Laboratories, Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRIXADI brixadi |
2025 | Brixadi | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
157 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Braeburn Inc. Exact reporting entity; no affiliate inference |
2025 | BRIXADI open payments reported associated product |
CMS Open Payments — General Payments 15883 supporting records · 5757 recipient NPIs · example record 1249056386 |
Brixadi · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
171 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 682 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 36 |
| Sertraline Hcl | Sertraline Hcl | 451 | 23 |
| Memantine Hcl | Memantine Hcl | 418 | 21 |
| Furosemide | Furosemide | 398 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 45 |
| Metformin Hcl | Metformin Hcl | 334 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 327 | 35 |
| Gabapentin | Gabapentin | 309 | 33 |
| Losartan Potassium | Losartan Potassium | 253 | 16 |
| Lisinopril | Lisinopril | 248 | 41 |
| Donepezil Hcl | Donepezil Hcl | 246 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 23 |
| Eliquis | Apixaban | 233 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 20 |
| Omeprazole | Omeprazole | 219 | 27 |
| Galantamine Hbr | Galantamine Hbr | 211 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 203 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 190 | 13 |
| Famotidine | Famotidine | 178 | 15 |
| Xarelto | Rivaroxaban | 171 | suppressed |
| Potassium Chloride | Potassium Chloride | 167 | 17 |
| Farxiga | Dapagliflozin Propanediol | 157 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 21 |
| Levetiracetam | Levetiracetam | 147 | suppressed |
| Allopurinol | Allopurinol | 143 | 13 |
| Topiramate | Topiramate | 140 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 107 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 101 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 100 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 99 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 95 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | suppressed |
| Nystatin | Nystatin | 88 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | suppressed |
| Digoxin | Digoxin | 79 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 74 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 71 | 11 |
| Tramadol Hcl | Tramadol Hcl | 71 | 20 |
| Carvedilol | Carvedilol | 68 | suppressed |
| Spironolactone | Spironolactone | 67 | 12 |
| Cilostazol | Cilostazol | 66 | suppressed |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Glipizide Er | Glipizide | 63 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | suppressed |
| Lorazepam | Lorazepam | 63 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 62 | suppressed |
| Primidone | Primidone | 62 | suppressed |
| Ibuprofen | Ibuprofen | 61 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 12 |
| Baclofen | Baclofen | 59 | suppressed |
| Calcitriol | Calcitriol | 59 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Carbamazepine | Carbamazepine | 52 | suppressed |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Jardiance | Empagliflozin | 52 | 11 |
| Acetic Acid | Acetic Acid | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 18 |
| Finasteride | Finasteride | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Glimepiride | Glimepiride | 47 | suppressed |
| Loperamide | Loperamide Hcl | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Alprazolam | Alprazolam | 45 | 11 |
| Ozempic | Semaglutide | 45 | suppressed |
| Glipizide | Glipizide | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 15 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 40 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Prednisone | Prednisone | 37 | 27 |
| Insulin Lispro | Insulin Lispro | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 20 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Kerendia | Finerenone | 33 | suppressed |
| Naproxen | Naproxen | 33 | 15 |
| Dutasteride | Dutasteride | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 31 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 18 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Brixadi | Buprenorphine | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 23 |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Ethosuximide | Ethosuximide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,433.69 · 80 records | ABBVIE INC. | ACTHAR, AIRSUPRA, Auvelity, BREZTRI, BRIXADI, CAPLYTA, CREON, Cologuard Collection Kit, Dyanavel XR, FANAPT, Kerendia, LINZESS, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REXULTI, SMARTVEST, SPRAVATO, SUBLOCADE, SUFLAVE, SUTAB, UBRELVY, VOWST, VRAYLAR, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brixadi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error